SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte ™

Reaches Agreement with European Medicines Agency on Second Confirmatory Trial for HyBryte™ On April 3, 2024, Soligenix, Inc. SNGX announced it has reached agreement with the European Medicines Agency (EMA) on the key design elements for a confirmatory Phase 3 trial of HyBryte (synthetic hypericin)…#reachesagreement #soligenixinc #phase3 #hybryte #grade1 #flash2 #fda #usfda #odd #suvax
Source: Reuters: Health - Category: Consumer Health News Source Type: news